Gilead says on track with hepatitis C treatments
(Reuters) - Gilead Sciences Inc is on track to file for regulatory approval of sofosbuvir, its treatment for chronic hepatitis C virus (HCV) infection, starting in mid-2013, the biotech company said on Monday.
Gilead is scheduled to give investors an update on its candidates for HCV treatment at a JPMorgan healthcare conference this week in San Francisco.
The company will discuss new results from an arm of a continuing Phase 2 trial and provide a progress report on a range of Phase 2 and 3 trials evaluating a once-daily fixed-dose combination tablet of the medicines.
(Reporting by Debra Sherman; editing by John Wallace)
- U.S. Mega Millions lottery up to $400 million, 2nd-biggest ever
- Uruguay becomes first country to legalize marijuana trade
- Pope Francis named Time's Person of the Year
- Thousands of South Africans line up to see Mandela lie in state |
- China bitcoin arbitrage ends as traders work around capital controls
Time magazine named Pope Francis as its Person of the Year, crediting him with shifting the message of the Catholic Church. Slideshow